Evaluation of Salmonella enterica serovar Typhi (Ty2 aroC-ssaV-) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers (Q46685348)

From Wikidata

Jump to navigation Jump to search

scientific article published on 18 August 2005

Language	Label	Description	Also known as
English	Evaluation of Salmonella enterica serovar Typhi (Ty2 aroC-ssaV-) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers	scientific article published on 18 August 2005

Statements

scholarly article

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/16140433

Evaluation of Salmonella enterica serovar Typhi (Ty2 aroC-ssaV-) M01ZH09, with a defined mutation in the Salmonella pathogenicity island 2, as a live, oral typhoid vaccine in human volunteers (English)

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/16140433

Salmonella enterica

0 references

typhoid vaccine

1 reference

based on heuristic

inferred from title

author name string

B D Kirkpatrick

1

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/16140433

Robin McKenzie

2

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/16140433

J Patrick O'Neill

3

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/16140433

Catherine J Larsson

4

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/16140433

A Louis Bourgeois

5

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/16140433

Janet Shimko

6

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/16140433

Matthew Bentley

7

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/16140433

Jill Makin

8

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/16140433

Steve Chatfield

9

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/16140433

Zoë Hindle

10

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/16140433

Christine Fidler

11

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/16140433

Brad E Robinson

12

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/16140433

Cassandra H Ventrone

13

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/16140433

Nivedita Bansal

14

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/16140433

Colleen M Carpenter

15

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/16140433

Deborah Kutzko

16

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/16140433

Sandra Hamlet

17

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/16140433

Casey LaPointe

18

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/16140433

David N Taylor

19

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/16140433

language of work or name

0 references

publication date

18 August 2005

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/16140433

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/16140433

24

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/16140433

2

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/16140433

116-123

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/16140433

Multidrug-resistant Salmonella typhi: a worldwide epidemic

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.008

7 January 2021

Enteric fever treatment failures: a global concern

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.008

7 January 2021

Widespread occurrence of multiple drug-resistantSalmonella typhi in India

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.008

7 January 2021

A massive epidemic of multidrug-resistant typhoid fever in Tajikistan associated with consumption of municipal water

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.008

7 January 2021

Epidemic ciprofloxacin-resistant Salmonella typhi in Tajikistan.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.008

7 January 2021

Quinolone-resistant Salmonella typhi in Viet Nam: molecular basis of resistance and clinical response to treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.008

7 January 2021

Live attenuated Salmonella: a paradigm of mucosal vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.008

7 January 2021

Optimization of Salmonella enterica serovar typhi DeltaaroC DeltassaV derivatives as vehicles for delivering heterologous antigens by chromosomal integration and in vivo inducible promoters

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.008

7 January 2021

Adaptation of the endogenous Salmonella enterica serovar Typhi clyA-encoded hemolysin for antigen export enhances the immunogenicity of anthrax protective antigen domain 4 expressed by the attenuated live-vector vaccine strain CVD 908-htrA.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.008

7 January 2021

Attenuated Salmonella enterica serovar Typhi and Shigella flexneri 2a strains mucosally deliver DNA vaccines encoding measles virus hemagglutinin, inducing specific immune responses and protection in cotton rats

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.008

7 January 2021

Progress toward the development of a bacterial vaccine vector that induces high-titer long-lived broadly neutralizing antibodies against HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.008

7 January 2021

Induction of protective immunity against Streptococcus mutans colonization after mucosal immunization with attenuated Salmonella enterica serovar typhimurium expressing an S. mutans adhesin under the control of in vivo-inducible nirB promoter.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.008

7 January 2021

Safety and immune responses to attenuated Salmonella enterica serovar typhi oral live vector vaccines expressing tetanus toxin fragment C.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.008

7 January 2021

Towards new immunotherapies: targeting recombinant cytokines to the immune system using live attenuated Salmonella.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.008

7 January 2021

Enteric pathogens as vaccine vectors for foreign antigen delivery

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.008

7 January 2021

Clinical acceptability and immunogenicity of CVD 908 Salmonella typhi vaccine strain.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.008

7 January 2021

Phase 2 clinical trial of attenuated Salmonella enterica serovar typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.008

7 January 2021

Characterization of Salmonella enterica derivatives harboring defined aroC and Salmonella pathogenicity island 2 type III secretion system (ssaV) mutations by immunization of healthy volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.008

7 January 2021

Genetic characteristics of the Salmonella typhi strain Ty21a vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.008

7 January 2021

Salmonella typhi and S typhimurium derivatives harbouring deletions in aromatic biosynthesis and Salmonella Pathogenicity Island-2 (SPI-2) genes as vaccines and vectors.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.008

7 January 2021

Specific immunoglobulin-secreting human blood cells after peroral vaccination against Salmonella typhi.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.008

7 January 2021

Antibody-secreting cells in the evaluation of the immunogenicity of an oral vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.008

7 January 2021

Characterization of a post-translational modification of Campylobacter flagellin: identification of a sero-specific glycosyl moiety.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.008

7 January 2021

phoP/phoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.008

7 January 2021

The novel oral typhoid vaccine M01ZH09 is well tolerated and highly immunogenic in 2 vaccine presentations

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.008

7 January 2021

Safety and immunogenicity of two Salmonella typhi Vi capsular polysaccharide vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.008

7 January 2021

Considerations regarding mass vaccination against typhoid fever as an adjunct to sanitation and public health measures: potential use in an epidemic in Tajikistan.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.008

7 January 2021

Bacteremic typhoid fever in children in an urban slum, Bangladesh

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.008

7 January 2021

Oral immunization with a Salmonella typhimurium vaccine vector expressing recombinant enterotoxigenic Escherichia coli K99 fimbriae elicits elevated antibody titers for protective immunity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.008

7 January 2021

based on heuristic

inferred from DOI database lookup

Mucosal immunogenicity of a recombinant Salmonella typhimurium-cloned heterologous antigen in the absence or presence of coexpressed cholera toxin A2 and B subunits.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.008

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and immunogenicity in humans of an attenuated Salmonella typhi vaccine vector strain expressing plasmid-encoded hepatitis B antigens stabilized by the Asd-balanced lethal vector system

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.008

7 January 2021

based on heuristic

inferred from DOI database lookup

Progress in vaccines against typhoid fever

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2005.08.008

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2005.08.008

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/16140433

1 reference

Europe PubMed Central

24 December 2017

http://europepmc.org/abstract/MED/16140433

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46685348&oldid=2126810005"